SPDR S&P Biotech ETF
414 hedge funds and large institutions have $5.13B invested in SPDR S&P Biotech ETF in 2018 Q1 according to their latest regulatory filings, with 69 funds opening new positions, 146 increasing their positions, 119 reducing their positions, and 45 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more funds holding in top 10
Funds holding in top 10: →
10.15% more ownership
Funds ownership: 96.2% → 106.36% (+10%)
4% more funds holding
Funds holding: 397 → 414 (+17)
57% less call options, than puts
Call options by funds: $691M | Put options by funds: $1.62B
Holders
414
Holding in Top 10
19
Calls
$691M
Puts
$1.62B
Top Buyers
| 1 | +$453M | |
| 2 | +$182M | |
| 3 | +$156M | |
| 4 |
Rafferty Asset Management
New York
|
+$121M |
| 5 |
CI
Clal Insurance
Tel-Aviv,
Israel
|
+$119M |
Top Sellers
| 1 | -$70.3M | |
| 2 | -$65.2M | |
| 3 | -$46.7M | |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$22.2M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$18.6M |